Gain Therapeutics (GANX) Set to Post Earnings on Wednesday

Gain Therapeutics (NASDAQ:GANX) will likely be posting its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Gain Therapeutics to announce earnings of ($0.13) per share and revenue of $0.03 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. On average, analysts expect Gain Therapeutics to post ($0.50) EPS for the current fiscal year and ($0.55) EPS for the next fiscal year.

Gain Therapeutics Price Performance

Shares of Gain Therapeutics stock opened at $1.15 on Wednesday. The company has a current ratio of 4.36, a quick ratio of 4.36 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $50.19 million, a price-to-earnings ratio of -2.30 and a beta of 0.29. Gain Therapeutics has a 1-year low of $1.11 and a 1-year high of $4.34. The firm’s 50-day moving average price is $1.59 and its two-hundred day moving average price is $1.85.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on GANX shares. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research note on Monday, October 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Friday, September 4th. Finally, BTIG Research reaffirmed a “buy” rating and set a $5.00 price target on shares of Gain Therapeutics in a report on Monday, October 5th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $7.67.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc is a biotechnology company focused on developing small-molecule therapies for diseases associated with lysosomal dysfunction, including neurodegenerative and rare disorders. The company’s approach is designed to identify compounds that bind to and modulate disease-related proteins, with the goal of restoring their function and addressing underlying disease mechanisms.

Gain Therapeutics’ lead investigational program, GT-02287, is an orally administered, brain-penetrant small molecule being developed for GBA1-associated Parkinson’s disease.